Rishi P. Singh, MD; and Michael A. Klufas, MD, provide an overview of the 2 currently available ophthalmology biosimilars, ranibizumab-eqrn and ranibizumab-nuna, as well as discuss which patient populations will benefit from these treatments.
Michael A. Klufas, MD, discusses issues with off-label bevacizumab use, focusing on compounding issues and decreases in clinical efficacy due to repackaging.
Expert retina specialists review the impact of biosimilars in clinical ophthalmology practice, highlighting the potential decrease of financial burden to the patient.